The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer

SIMPLE SUMMARY: Breast and lung cancers are the most diagnosed cancers in the United States. Despite advances in treatment, over 176,000 deaths are expected in 2021, highlighting the need for new therapies. We evaluated MSU42011, a new RXR receptor activator, in murine models of breast and lung canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Leal, Ana S., Moerland, Jessica A., Zhang, Di, Carapellucci, Sarah, Lockwood, Beth, Krieger-Burke, Teresa, Aleiwi, Bilal, Ellsworth, Edmund, Liby, Karen T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508021/
https://www.ncbi.nlm.nih.gov/pubmed/34638488
http://dx.doi.org/10.3390/cancers13195004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508021/
https://www.ncbi.nlm.nih.gov/pubmed/34638488
http://dx.doi.org/10.3390/cancers13195004

Ejemplares similares